Real-World Study of Treatment Patterns and Outcomes in Adult Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Androgen Receptor Pathway Inhibitors, Taxane Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

What this Trial Is About

This research evaluates treatment patterns, patient characteristics, and clinical outcomes in adult men with metastatic castration-resistant prostate cancer mCRPC who have previously received at least one androgen receptor pathway inhibitor ARPI, one taxane chemotherapy, and Lutetium-177 Vipivotide Tetraxetan 177Lu-PSMA-617. The study uses real-world data collected from the PRECISION data platform in the United States to better understand how these treatments are applied and their impact. Participants are grouped into an overall mCRPC cohort who have received prior treatments including ARPI, taxane, and 177Lu-PSMA-617. Subgroups include patients who show disease progression after 177Lu-PSMA-617 treatment and those who start at least one new systemic therapy after the index treatment. The index date is defined as the last administration date among their latest ARPI, taxane, or 177Lu-PSMA-617 treatment. During the study, researchers collect data on the number and types of prior therapies, timing and number of PSMA scans, lines of therapy before and after the index date, and time to next therapy initiation, monitoring these outcomes for up to approximately five years. Additional measures include patient characteristics, progression-free survival, overall survival, and biomarkers like PSA levels. The study spans from June 2026 to November 2026, focusing on real-world outcomes without administering treatments directly.

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan